Clinical trials: Regional Citrate Anticoagulation
Regional Citrate Anticoagulation (RCA), Continuous Renal Replacement Therapy (CRRT)
Safety Evaluation of Prismocitrate 18 in Patients Receiving CRRT
Prismocitrate 18 is a continuous renal replacement therapy (CRRT) solution to be used as a renal replacement solution and as an anticoagulant to prevent blood clotting in the extracorporeal circuit.
- Conditions
- Regional Citrate Anticoagulation (RCA), Continuous Renal Replacement Therapy (CRRT), Acute Kidney Injury (AKI)
- Trial name
- NCT05399537
- Testing
- Prismocitrate 18, PrisMax System Version 3.x with calcium line accessory
- Where
- 14 sites in United States
- Volunteers
- 40 people
- Sponsor
- Vantive Health LLC
Renal Injury, Regional Citrate Anticoagulation
Effects of Different Continuous Renal Replacement Therapy Patterns on Ionized Calcium in Patients With Citrate Anticoagulants Using Calcium-containing Replacement Solutions
It is unclear whether different modes of continuous renal replacement therapy (CRRT) impact post-filter ionized calcium concentrations during regional citrate anticoagulation (RCA) when using calcium-containing replacement fluid.
- Conditions
- Renal Injury, Regional Citrate Anticoagulation, Continuous Renal Replacement Therapy
- Trial name
- NCT06021080
- Testing
- CVVH, CVVHD
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Fujian Provincial Hospital
Regional Citrate Anticoagulation (RCA), Continuous Renal Replacement Therapy (CRRT)
Clinical Evaluation of Use of Prismocitrate 18 in Patients Undergoing Acute Continuous Renal Replacement Therapy (CRRT)
The purpose of this research is to determine if an investigational new drug solution called Prismocitrate 18 lengthens extracorporeal circuit life in patients treated with continuous renal replacement therapy (CRRT).
- Conditions
- Regional Citrate Anticoagulation (RCA), Continuous Renal Replacement Therapy (CRRT), Acute Kidney Injury
- Trial name
- NCT02860130
- Testing
- Prismocitrate 18, No Anticoagulation
- Where
- 12 sites in United States, Canada
- Volunteers
- 34 people
- Sponsor
- Vantive Health LLC
Critically Ill, Acute Kidney Injury
Comparison of Biphozyl® and Phoxilium® as a Replacement Fluid During CVVH for AKI in Adults and Their Effects on pH-, Bicarbonate-levels and Respiratory Situation
The primary objectives of the BiPhox-Trial are to demonstrate, that the use of Biphozyl® as a replacement fluid in adult critically ill acute kidney injury (AKI) patients, results in a lower rate of pH excursions and of…
- Conditions
- Critically Ill, Acute Kidney Injury, Renal Replacement Therapy, Continuous Renal Replacement Therapy
- Trial name
- NCT04071171
- Testing
- CVVH with Phoxilium® in the first 48h after randomization, CVVH with Biphozyl® in the first 48h after randomization, CVVH with Phoxilium® in the second 48h after randomization (after previous 48h with Biphozyl®)
- Where
- Austria
- Volunteers
- 88 people
- Sponsor
- Medical University Innsbruck
Regional Citrate Anticoagulation, Ionized Calcium
No Monitoring of Post-filter Ionized Calcium in Regional Citrate Anticoagulation
Do no monitor of post-circuit ionized calcium affact the filter life time of continueous renal replacement therapy with regional citrate anticoagulation circuit? A randomized control trial
- Conditions
- Regional Citrate Anticoagulation, Ionized Calcium, Continuous Renal Replacement Therapy
- Trial name
- NCT04792424
- Testing
- Regional citrate anticoagulation, Vasopressor, Antibiotic
- Where
- Thailand
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Chulalongkorn University
Citrate Toxicity, Regional Citrate Anticoagulation
Citrate Pharmacokinetics in Critically Ill Liver Failure Patients Receiving CRRT
Citrate has been proposed as anticoagulation of choice in continuous renal replacement therapy (CRRT). However, little is known about the pharmacokinetics (PKs) and metabolism of citrate in liver failure patients who require CRRT…
- Conditions
- Citrate Toxicity, Regional Citrate Anticoagulation, Liver Failure, Acute, Liver Failure, Acute on Chronic
- Trial name
- Citrate PK (NCT04959110)
- Testing
- Pharmacokinetic study
- Where
- Thailand
- Volunteers
- 20 people
- Sponsor
- Chulalongkorn University